非药物干预对肥胖个体抑郁症的影响:一个网络元分析
Zhilin Chen1, Ruiqing Wang1, Yiwei Wang1
1College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Frontiers in psychiatry
|March 4, 2026
概括
认知行为疗法 (CBT) 显示出减轻肥胖个体抑郁症状的前景. 然而,研究质量限制了确定性,其他干预措施 (如BT+LI和PMBI) 也在特定的抑郁症尺度上显示出好处.
科学领域:
- 肥胖和心理健康 肥胖和心理健康
- 临床心理学 临床心理学
- 基于证据的医学基于证据的医学.
背景情况:
- 肥胖和抑郁症经常同时发生,影响生活质量.
- 非药物干预措施是有效的,但比较有效性尚不清楚.
- 患有抑郁症的超重和肥胖个体需要优化治疗策略.
研究的目的:
- 进行网络元分析 (NMA),比较超重/肥胖个体对抑郁症状的非药物干预措施.
- 确定最有效的干预措施,以改善这一群体的心理健康结果.
- 根据它们的比较有效性对干预措施进行排名.
主要方法:
- 系统地搜索Embase,PubMed,Cochrane图书馆和科学网络中的RCT.
- 包括36个RCT,共有11,153名参与者和16个干预措施.
- 采用标准化平均差异 (SMD) 和平均差异 (MD) 的聚合分析,通过SUCRA值进行干预排名.
主要成果:
- 认知行为疗法 (CBT) 在整体排名中排名最高 (77.8%).
- 具体干预措施在特定的抑郁症等级上表现出很高的排名:BDI-II的BT+LI (97.6%),PHQ-9的CBT-CI (97.9%),CES-D的PMBI (84.5%).
- 由于网络数据稀疏或间接,BDI-II和HADS的排名应谨慎解释.
结论:
- 在减轻超重/肥胖个体的抑郁症状方面,CBT似乎有效,尽管总体证据确定性有限.
- 行为疗法加上生活方式干预 (BT+LI) 和心理社会和心身干预 (PMBI) 在特定的抑郁症措施上显示出希望.
- 需要进一步的高质量研究来证实各种非药理学策略的比较有效性.
相关概念视频
Antidepressant Drugs: Overview
2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K
Antidepressant Drugs: MAOIs and Other Agents
1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Obesity
1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Drug Dosing: Obese Patients
368
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
368
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
440
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
440
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
324
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324


